A simple home-based exercise program may help combat “chemical brain,” but adding ibuprofen does not improve effectiveness and may even complicate memory results, highlighting the need for larger trials.
Study: Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy. Image credit: Pixel-Shot/Shutterstock.com
Preliminary findings suggest that exercise and low-dose ibuprofen alone, but not in combination, may improve some aspects of cancer-related cognitive impairment (CRCI) in patients receiving chemotherapy. The paper was published in a magazine cancer.
Chemotherapy-related cognitive decline associated with inflammatory processes
CRCI affects up to 80% of cancer patients undergoing chemotherapy, a condition known as “chemobrain” and is thought to result in part from inflammation. Exercise has been shown to help reduce fatigue, mental distress, and functional decline associated with cancer.
Exercise for Cancer Patients©® (EXCAP) is a home-based, 6-week program for cancer patients that includes low-to-moderate-intensity exercise, progressive walking, and prescribed resistance exercise. Its anti-inflammatory effects in chemotherapy patients have been described in previous studies by the authors of the current study.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that may have potential efficacy against CRCI at low doses, but this has not yet been clinically established.
The aim of the current phase 2 trial was to confirm the preliminary efficacy of these agents in preventing or reducing the severity of CRCI in sedentary patients receiving chemotherapy. Although no significant interactions were observed between the two interventions in this study, additive or synergistic effects are possible as their effects may occur through different pathways.
Phase 2 trial tests combination of exercise and ibuprofen
The study included 86 participants (mean age 54 years), almost all of whom were non-Hispanic, non-Latino white women. Most were married, employed, and had breast cancer.
Participants were randomly assigned to EXCAP-ibuprofen, EXCAP-placebo, ibuprofen only, and placebo only groups.
Ibuprofen and placebo were administered at 200 mg twice daily for 6 weeks in a double-blind manner. Cognitive tests were performed at baseline regarding memory, attention, and executive function. Immune markers, fitness assessments, and anxiety and depression measures were also obtained from all participants.
EXCAP promotes activities
In the EXCAP group, the number of daily steps increased over time from sedentary to less active levels. The EXCAP group walked an average of 5,650 steps per day, while the non-EXCAP group walked 3,982 steps per day.
In the EXCAP group, the number of people walking more than 5000 steps per day also increased over time (from 30% at baseline to 51% post-intervention).
Selective improvement with exercise and ibuprofen
Improved attentiveness
Compared to placebo, the EXCAP-placebo group showed the strongest improvement in alertness, followed by the ibuprofen-only group. These effects were primarily observed in attention-related tests such as the trail-making test.
Specifically, participants in the placebo group experienced worsening of attention over time, whereas participants in the EXCAP-Placebo group improved. This contrast highlights the potential of exercise to counter cognitive decline during chemotherapy.
Speeding up information processing
Additionally, participants in the EXCAP placebo group demonstrated improved performance on fast visual processing tasks, reflected in reduced response latencies. A similar but weaker trend was observed in the ibuprofen group, suggesting a possible but less consistent effect on processing speed.
Patient-reported cognitive changes
Both EXCAP groups reported better scores on the “Comments from Others” subscale of the FACT-Cog compared to placebo. This indicates that participants perceived an improvement in how others viewed their cognitive functioning.
The EXCAP-ibuprofen group showed the greatest improvement, and the EXCAP-placebo group showed a positive trend. However, these effects are limited to this particular subscale and do not extend to all measures of perceived cognition.
Different effects on memory
Effects on memory were inconsistent. Participants who received ibuprofen showed less improvement in delayed verbal memory (Hopkins Verbal Learning Test-Revised) compared to participants who did not receive ibuprofen, suggesting there may be negative or variable effects on this area.
Within-group memory improvements were observed across several groups, but there were no significant differences between intervention groups.
No consistent benefit across all cognitive domains
Despite improvements in attention and processing speed, many cognitive outcomes, including visual memory and executive function, did not differ significantly between the groups. Some improvements observed over time may reflect common study participation or repeated testing rather than a true intervention effect.
There is no additional benefit from combining interventions
Exercise and ibuprofen each showed some independent effects, but their combination did not produce any additional cognitive effects.
strengths and limitations
The study followed a randomized controlled trial (RCT) design conducted during chemotherapy rather than after chemotherapy. Different types and stages of cancer were included. Comprehensive cognitive testing and high compliance rates increase the value of findings.
However, some limitations exist. The main reasons are the small sample size, the lack of a statistically significant interaction between EXCAP and ibuprofen, and the lack of diversity in major cancer types and ethnic composition.
This result suggests that exercise may effectively reduce certain aspects of cognitive impairment during chemotherapy. Low doses of ibuprofen also produced improvements, albeit weaker, on some measures, with mixed results in other areas, including potential negative effects on verbal memory.
Because this study only evaluated short-term results over 6 weeks and not durability after the intervention ended, findings will need to be confirmed in a longer phase 3 trial to assess long-term efficacy.
Click here to download your PDF copy.
